Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

April 30, 2019



Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)




Delaware   001-38720   46-205888
(State or other jurisdiction of   (Commission File Number)   (I. R. S. Employer
incorporation)     Identification No.)

455 Mission Bay Boulevard South

Suite 545

San Francisco, CA 94158

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 7.01

Results of Operations and Financial Condition.

On April 30, 2019, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended March 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.







99.1    Press release dated April 30, 2019 titled “Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress.”


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 30, 2019


Twist Bioscience Corporation


/s/ Mark Daniels


Mark Daniels


Senior Vice President, Chief Legal Officer, Chief

Ethics and Compliance Officer, and Secretary


Exhibit 99.1



Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights

Commercial and Operational Progress

— Reports Record Revenue of $13.6 Million for Second Quarter of Fiscal 2019 —

— Increasing Orders Show Sequential Growth in Synthetic Biology and Next-Generation

Sequencing Products —

— Updates Fiscal 2019 Financial Guidance —

SAN FRANCISCO, Calif. – April 30, 2019 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2019 ended March 31, 2019.

“We continue to post strong topline growth as we extend our reach and diversify our revenue stream from our synbio customers,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “For NGS, we continue to expand our base of customers rapidly, adding several in production and a larger number in pilot. Importantly, we launched our biopharma capabilities in April at The Essential Protein Engineering Summit, or PEGS, the beginning of what promises to be an exciting division of the company.”

Leproust continued, “This quarter, we reported a positive gross margin of $1.8 million, and we expect to continue to improve our operational synergies and increase capacity. In the current quarter we will be expanding our manufacturing facilities in South San Francisco and we will be extending our ISO 13485:2016 for our quality management systems for NGS at this new facility.”




Orders: Total orders received for the three months ended March 31, 2019 were $16.7 million, compared to $8.5 million for the same period of fiscal 2018.



Revenue: Total revenues were $13.6 million for the three months ended March 31, 2019 compared to $6.2 million for the same period of fiscal 2018.



Cost of Revenues: Cost of revenues for the three months ended March 31, 2019 was $11.8 million compared to $8.1 million for the similar period of fiscal 2018.



Research and Development Expenses: Research and development expenses for the three months ended March 31, 2019 were $8.9 million compared to $4.7 million for the same period of fiscal 2018.



Selling, General and Administrative Expenses: Selling, general and administrative expenses for the three months ended March 31, 2019 were $19.1 million compared to $10.0 million for the same period of fiscal 2018.


Net Loss: Net loss for the fiscal 2019 second quarter was $25.9 million, or $0.93 per share, compared to $16.9 million, or $6.32 per share, for the fiscal 2018 second quarter.



Cash Position: As of March 31, 2019, the company had $104.3 million in cash, cash equivalents and short term investments.

“In addition to raising our revenue guidance based on strong first half results, our positive gross margin of $1.8 million, or 13 percent of revenue, reflects the impact of scaling our business, higher NGS product revenues, our organization executing well and leveraging the cost advantages of our proprietary DNA synthesis platform,” commented Jim Thorburn, CFO of Twist.

Fiscal Second Quarter 2019 and Recent Highlights



Continued diversification of synthetic biology revenue



Current turnaround time for 1.8 kb genes decreased to 13 days; turnaround time for 3-5kb genes decreased to 14 days



Continued conversion of NGS product line customers, having shipped to >100 customers in the second quarter of fiscal 2019 with 24 customers now in production mode



Introduced new products for NGS early access customers at the 2019 Advances in Genome Biology and Technology (AGBT) meeting. New products include Twist Fast Hybridization and Wash Kit, Twist Universal Blockers to allow flexible blocking and improved on-target capture; the Twist Universal Adapter System, to maximize performance for library preparation and enabling high multiplexing; and, the Twist Mechanical Fragmentation Library Prep Kit for highly-degraded samples



Presented early proof-of-concept data from the GPCR library and antibody optimization solution for Twist Biopharma at the annual PEGS meeting



Formed strategic collaboration with LakePharma to provide antibody discovery and development services



Signed antibody optimization agreement with Pandion Therapeutics to apply our antibody optimization solution to the targeting arm of a bispecific antibody



Began contract negotiations with a government entity for a non-dilutive financing contract to facilitate DNA data storage



Expanded the biosecurity program with the addition of Battelle’s ThreatSEQ for DNA screening



Announced move of manufacturing facilities into South San Francisco

Fiscal 2019 Objectives




Offer customers 5kb genes at disruptive price – Complete



Introduce Twist Application Programmable Interface (TAPI) for gene ordering – Complete



Implement and execute new product introductions roadmap

Genomics and Targeted NGS



Achieve ISO 13485:2016 certification for quality management systems (NGS TE Panels) – Complete; Extension for South San Francisco facility to be completed early 4QFY19



Convert pilot NGS customers to full production – Ongoing



Launch e-commerce platform for NGS products in the first half of 2019



Leverage growth in top line to improve variable and gross margin



Launch back-end production in China for NGS and other products




Generate early proof-of-concept data from the GPCR library and antibody optimization software for Twist Biopharma – Complete



Expand proof of concept data packages for the GPCR antibody library and the bio-better programs



Advance the antibody discovery and optimization programs through non-dilutive collaborations—Ongoing



Longer-term: seek revenue-generating partnerships

DNA Data Storage



Execute roadmap to increase synthesis density on silicon platform and reduce DNA writing cost for DNA digital data storage



Pursue non-dilutive funding for the continued development of DNA digital data storage

Financial Guidance

For the full fiscal year 2019, Twist is updating its guidance:



Revenue in the range of $50 million to $52 million



Net loss in the range of $97 million to $99 million to reflect accelerated investment in R&D, consistent with our strategy to continually offer improved products and new offerings to solidify our leadership position in the space. We continue to invest in our commercial organization as we anticipate revenue growth. In addition, we expect additional incremental costs associated with our China facility build-out and the consolidation of our operations and R&D efforts at our SSF facility. We believe these investments position us for continued growth in the near- and long-term.

Conference Call Information

The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 2244119. A telephonic replay of the conference call will be available beginning approximately four hours after the call through May 7, 2019 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 2244119. The webcast replay will be available at www.twistbioscience.com.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Investor Relations Information

Twist uses the investor relations section on its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Twist’s investor relations website in addition to following Twist’s press releases, SEC filings, and public conference calls and webcasts.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Twist Bioscience’s anticipated fiscal 2019 milestones, conversion of pilot customers, revenue growth across all product categories and geographic regions, validation of Twist’s GPCR and antibody optimization software for Twist Biopharma and delivery on Twist’s mission to improve healthcare and sustainability through synthetic DNA. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 20, 2018 relating to its initial public offering of common stock. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.


Investor Contact:

Argot Partners

Maeve Conneighton



Media Contact:

Angela Bitting

925- 202-6211


# # #

Twist Bioscience Corporation

Condensed Consolidated Statements of Operations


(in thousands, except share and per share data)


     Three Months Ended March 31,     Six Months Ended March 31,  
     2019     2018     2019     2018  


   $ 13,557     $ 6,166     $ 25,049     $ 10,479  

Operating expenses:


Cost of revenues

     11,789       8,095       23,646       15,593  

Research and development

     8,907       4,711       16,180       9,014  

Selling, general and administrative

     19,124       9,978       34,383       19,241  













Total operating expenses

     39,820       22,784       74,209       43,848  













Loss from operations

     (26,263     (16,618     (49,160     (33,369

Interest income

     775       148       1,439       306  

Interest expense

     (340     (317     (688     (590

Other income (expense), net

     (21     (43     (36     (62

Provision for income taxes

     (84     (43     (127     (95













Net loss attributable to common shareholders

   $ (25,933   $ (16,873   $ (48,572   $ (33,810













Net loss per common share, basic and diluted

   $ (0.93   $ (6.32   $ (2.06   $ (12.74













Shares used to compute net loss per common share, basic and diluted

     27,891,700       2,669,541       23,539,617       2,653,805  













Twist Bioscience Corporation

Condensed Consolidated Balance Sheet

(in thousands)


     March 31, 2019      September 30, 2018  
     (Unaudited)      (1)  



Cash and cash equivalents

   $ 28,693      $ 80,757  

Short-term investments

     75,631        —    

Accounts receivable, net

     7,998        5,419  


     4,449        6,028  

Prepaid expenses and other current assets

     4,220        3,467  







Total current assets

     120,991        95,671  

Property and equipment, net

     14,940        12,331  

Other assets

     4,239        7,789  







Total assets

     140,170        115,791  







Current liabilities


Accounts payable

   $ 4,505      $ 7,531  

Accrued liabilities

     9,848        7,567  

Current portion of long-term debt

     3,333        2,500  

Other current liabilities

     894        939  







Total current liabilities

     18,580        18,537  

Redeemable convertible preferred stock warrant liability

     —          631  

Long-term debt, net of current portion

     5,828        7,218  

Other non-current liabilities

     282        344  







Total liabilities

     24,690        26,730  

Redeemable convertible preferred stock

     —          290,483  







Total stockholders’ equity (deficit)

     115,480        (201,422







Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)

   $ 140,170      $ 115,791  









The condensed balance sheet as of September 30, 2018 has been derived from the audited financial statements at that date included in the Company’s Form 10-K filed with the Securities and Exchange Commission dated December 20, 2018.